Search results for "Milan criteria"

showing 10 items of 21 documents

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

Hepatocellular carcinoma in Child's A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection accord…

2013

This is the first matched pair analysis on the puzzling clinical problem of whether to perform liver transplantation (LT) or liver resection (LR) for Child's A hepatocellular carcinoma (HCC) patients. A total of 201 patients diagnosed with HCC and Child's A liver cirrhosis were treated with LT transarterial chemoembolization (TACE) or LR between 1998 and 2012. To achieve the most accurate study design, two groups of 57 patients were matched retrospectively according to their tumor characteristics detected by the initial computerized tomography (CT) scan. Sixteen of 57 LT candidates were not transplanted due to tumor progress during pre-treatment (TACE). Nevertheless, the retrospective analy…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentMatched-Pair AnalysisMilan criteriaLiver transplantationGastroenterologyResectionRecurrenceInternal medicinemedicineRetrospective analysisHepatectomyHumansIn patientAgedRetrospective StudiesAged 80 and overTransplantationIntention-to-treat analysisbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisIntention to Treat AnalysisLiver TransplantationSurvival RateHepatocellular carcinomaFemalebusinessFollow-Up StudiesClinical transplantation
researchProduct

Five-Year Survival After Monotherapy for Hepatocellular Carcinoma in the Setting of Cirrhosis

2008

The purpose of this study was to evaluate the long-term results with monotherapy for hepatocellular carcinoma (HCC) in the setting of cirrhosis. We reviewed data of 14 patients who survived for at least 5 years after performance of liver resection (n = 1), transarterial chemoembolization (TACE, n = 3), or liver transplantation (OLT, n = 19). Eight patients were within the Milan criteria, whereas the remaining 6 were beyond the criteria. Tumor stages according to the UICC were I (n = 8), II (n = 5), and IIIA (n = 1). Vascular invasion was not detected in any patient. The HCCs recurred in 2 patients, at 81 and 48 months' posttransplant. Sites of recurrence were the intrathoracic lymph nodes i…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentMedizinMilan criteriaLiver transplantationGastroenterologyInternal medicinemedicineCarcinomaHumansSurvivorsChemoembolization TherapeuticSurvival rateAgedTransplantationbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseLiver TransplantationSurgerySurvival RateTransplantationHepatocellular carcinomaFemaleSurgeryalpha-FetoproteinsNeoplasm Recurrence LocalbusinessLiver cancerFollow-Up StudiesTransplantation Proceedings
researchProduct

Liver transplantation for hepatocellular carcinoma--is there a risk of recurrence caused by intraoperative blood salvage autotransfusion?

2011

<i>Background/Aims:</i> The use of intraoperative blood salvage autotransfusion (IBSA) during surgical approaches may contribute to tumour cell dissemination. Therefore, IBSA should be avoided in cases of malignancy. However, the risks of IBSA might be acceptable in liver transplantation (LT) for selected small hepatocellular carcinoma (HCC). <i>Methods:</i> In total, 136 recipients of LT with histologically proven HCC in the explanted liver were included in this analysis. With regard to tumour recurrence, 40 patients receiving IBSA despite HCC (IBSA group) were compared to 96 patients without IBSA (non-IBSA group). <i>Results:</i> Milan criteria as asses…

AdultMalemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationMilan criteriaNeoplasm RecurrenceRisk FactorsmedicineCarcinomaHumansAgedSurgical approachIntraoperative blood salvagebusiness.industryOperative Blood SalvageLiver NeoplasmsMiddle Agedmedicine.diseaseNeoplastic Cells CirculatingSurgeryLiver TransplantationHepatocellular carcinomaSurgeryFemaleRadiologyNeoplasm Recurrence LocalbusinessAutotransfusionEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes
researchProduct

Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance

2011

BACKGROUND: The aetiological factors of hepatocellular carcinoma may vary over time. AIMS: The study assessed the potential impact of the aetiological factors on the effectiveness of surveillance in real-world patients. METHODS: Multicentre, cross-sectional study enrolling consecutive hepatocellular carcinoma cases during a six month period. RESULTS: 1733 cases (1311 prevalent and 422 incident) were recruited (mean age 68.6 years; 46.1% cases over 70 years; 73.9% males; 95.3% with cirrhosis); 63.0% were hepatitis C virus positive and 23.7% were virus negative. Amongst incident HCCs, 34.5% were single ≤3cm and 54.4% met the Milan criteria; 61.6% were diagnosed during surveillance; virus nega…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularEpidemiologyHepatocellular carcinomaCross-sectional studyCancer stageCancer stage; Epidemiology; Hepatitis; Hepatocellular carcinoma; Surveillance; Age Distribution; Aged; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B Surface Antigens; Hepatitis C Antibodies; Humans; Incidence; Italy; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prevalence; Ultrasonography; Population Surveillance; Hepatology; GastroenterologyMilan criteriaHepatitisAge DistributionInternal medicineEpidemiologyPrevalenceCarcinomaHumansMedicineHCCAgedUltrasonographyHepatitisHepatitis B Surface AntigensSurveillanceHepatologybusiness.industryIncidenceIncidence (epidemiology)CarcinomaLiver NeoplasmsCancer stage Epidemiology Hepatitis Hepatocellular carcinoma SurveillanceGastroenterologyHepatocellularHepatitis C AntibodiesMiddle Agedmedicine.diseaseETIOLOGYSurgeryCross-Sectional StudiesLogistic ModelsItalyHepatitis C Virus PositivePopulation SurveillanceHepatocellular carcinomaMultivariate AnalysisSURBVEILLANCEFemalebusiness
researchProduct

Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.

2021

IMPORTANCE: Accurate preoperative prediction of hepatocellular carcinoma (HCC) recurrence after liver transplant is the mainstay of selection tools used by transplant-governing bodies to discern candidacy for patients with HCC. Although progress has been made, few tools incorporate objective measures of tumor biological characteristics, resulting in inclusion of patients with high recurrence rates and exclusion of others who could otherwise be cured. OBJECTIVE: To externally validate the New York/California (NYCA) score, a recently published multi-institutional US HCC selection tool that was the first model incorporating a dynamic α-fetoprotein response (AFP-R) and compare the validated sco…

MaleOncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatment030230 surgeryLiver transplantationMilan criteriaRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansCumulative incidenceAgedProportional Hazards ModelsRetrospective StudiesReceiver operating characteristicbusiness.industryLiver NeoplasmsRegression analysisMiddle Agedmedicine.diseaseRegressionLiver TransplantationSurvival RateTransplantationROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaFemaleSurgeryalpha-Fetoproteinsbusiness
researchProduct

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

2006

Criteria to select patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) are based on tumor size and number of nodules rather than on tumor biology. The present study was undertaken to assess the role of transarterial chemoembolization (TACE) in selecting patients with tumors suitable for LT. Ninety-six consecutive patients with HCC were treated by repeatedly performed TACE, 62 of them exceeding the Milan criteria. Patients meeting the Milan criteria were immediately listed, and patients beyond the listing criteria were listed upon downstaging of the tumor following successful TACE. Fifty patients were finally transplanted. Of these 50 patients, 34 exceeded the Milan c…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationMilan criteriaGastroenterologyRecurrenceInternal medicineCarcinomaMedicineHumansChemoembolization TherapeuticSurvival rateRetrospective StudiesTransplantationHepatologybusiness.industryPatient SelectionLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateTreatment OutcomeHepatocellular carcinomaRelative riskDisease ProgressionSurgeryFemalebusinessLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer

2017

The debate about the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still ongoing. This study aims to identify the best variables allowing to discriminate between "high-" and "low-benefit" patients. To do so, the concept of intention-to-treat (ITT) survival benefit of LT has been created. Data of 2,103 adult HCC patients consecutively enlisted during the period 1987-2015 were analyzed. Three rigorous statistical steps were used in order to create the ITT survival benefit of LT: the development of an ITT LT and a non-LT survival model, and the individual prediction of the ITT survival benefit of LT defined as the difference between…

Malemedicine.medical_specialtySettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatment030230 surgeryMilan criteriaLiver transplantation03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver Transplantation; HepatologyHumansRisk factorHepatology; hepatocellular cancer; liver transplantationCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver TransplantationSurvival analysisRetrospective StudiesIntention-to-treat analysisHepatologybusiness.industryCarcinomaLiver NeoplasmsRetrospective cohort studyHepatocellularHepatologyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationSettore MED/18Europehepatocellular cancer030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patie…

2020

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentInternational CooperationPROGNOSTIC SCORETumor burdengastroenterologyLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCORELiver transplantationMilan criteriaRisk AssessmentLiver diseaseInternal medicinemedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapiesHEPATOCELLULAR CARCINOMARetrospective StudiesOUTCOMEFramingham Risk ScoreHepatologybusiness.industryPoorly differentiatedLiver Neoplasmshepatocelluar cancerMiddle Agedmedicine.diseasePrognosisSettore MED/18Liver TransplantationRISK FACTORSHepatocellular carcinomaCohortlocoregional therapiesFemalebusinessHepatology (Baltimore, Md.)References
researchProduct

Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular ca…

2013

Locoregional therapy (LRT) is being increasingly used for the management of hepatocellular cancer (HCC) in patients listed for liver transplantation (LT). Although several selection criteria have been developed, stratifications of survival according to the pathology of explanted livers and pre-LT LRT are lacking. Radiological progression according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and alpha-fetoprotein (AFP) behavior was reviewed for 306 patients within the Milan criteria (MC-IN) and 116 patients outside the Milan criteria (MC-OUT) who underwent LRT and LT between January 1999 and March 2010. A prospectively collected database originating from 6 collabor…

OncologyTransplantationmedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentMilan criteriaLiver transplantationmedicine.diseaseSurgeryTransplantationResponse Evaluation Criteria in Solid TumorsTumor progressionInternal medicineCarcinomaMedicineSurgeryRisk factorbusinessProspective cohort studyLiver Transplantation
researchProduct